GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » Pre-Tax Income

SLN (Silence Therapeutics) Pre-Tax Income : $-42.93 Mil (TTM As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Silence Therapeutics's pretax income for the three months ended in Dec. 2024 was $23.74 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-42.93 Mil. Silence Therapeutics's pretax margin was 97.57%.

During the past 13 years, Silence Therapeutics's highest Pretax Margin was -101.55%. The lowest was -23190.91%. And the median was -513.58%.


Silence Therapeutics Pre-Tax Income Historical Data

The historical data trend for Silence Therapeutics's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Pre-Tax Income Chart

Silence Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -49.12 -61.89 -49.65 -53.27 -44.46

Silence Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.15 -4.25 -22.06 -40.36 23.74

Competitive Comparison of Silence Therapeutics's Pre-Tax Income

For the Biotechnology subindustry, Silence Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Pre-Tax Income falls into.



Silence Therapeutics Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Silence Therapeutics's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-49.582+0.646+0+4.472+0
=-44.46

Silence Therapeutics's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=10.659+0+0+0.887+12.19
=23.74

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silence Therapeutics  (NAS:SLN) Pre-Tax Income Explanation

Silence Therapeutics's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=23.736/24.328
=97.57%

During the past 13 years, Silence Therapeutics's highest Pretax Margin was -101.55%. The lowest was -23190.91%. And the median was -513.58%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Silence Therapeutics Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.